Last reviewed · How we verify
Allopurinol Tablet
Allopurinol inhibits xanthine oxidase, an enzyme that converts hypoxanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid levels.
Allopurinol inhibits xanthine oxidase, an enzyme that converts hypoxanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid levels. Used for Chronic gout and hyperuricemia, Prevention of acute gout attacks, Uric acid nephropathy and kidney stone prevention.
At a glance
| Generic name | Allopurinol Tablet |
|---|---|
| Also known as | Xanthine oxidase inhibitor |
| Sponsor | Haiphong University of Medicine and Pharmacy |
| Drug class | Xanthine oxidase inhibitor |
| Target | Xanthine oxidase |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Metabolic disorders |
| Phase | FDA-approved |
Mechanism of action
Allopurinol is a purine analog that competitively inhibits xanthine oxidase, the final enzyme in the purine degradation pathway. By blocking this enzyme, it decreases the production of uric acid from purine metabolism, leading to lower serum uric acid concentrations and reduced uric acid crystal deposition in tissues and joints. This mechanism prevents acute gout attacks and the formation of uric acid kidney stones.
Approved indications
- Chronic gout and hyperuricemia
- Prevention of acute gout attacks
- Uric acid nephropathy and kidney stone prevention
- Hyperuricemia secondary to malignancy or chemotherapy
Common side effects
- Rash
- Nausea
- Diarrhea
- Headache
- Allopurinol hypersensitivity syndrome
- Hepatotoxicity
Key clinical trials
- A Study of Dotinurad Versus Allopurinol in Tophaceous Gout (PHASE3)
- A Study of Dotinurad Versus Allopurinol in Participants With Gout (PHASE3)
- Phentermine/Topiramate for Uric Acid Stones (PHASE3)
- HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness (PHASE4)
- Allopurinol and Pathogenesis of Cirrhosis (PHASE1, PHASE2)
- Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients (PHASE2)
- Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets (PHASE4)
- Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allopurinol Tablet CI brief — competitive landscape report
- Allopurinol Tablet updates RSS · CI watch RSS
- Haiphong University of Medicine and Pharmacy portfolio CI